Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs for Refractory Severe Systemic Scleroderma
NCT02213705Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2014
- Primary completion
- Feb 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MSV alogénicas in systemic sclerosis (SSc), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Immediate Toxicity at 10 days. Started May 2014; status: completed.
02
Drugs
MSV alogénicas
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT02213705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213705.